Overall rank by patents
#34,395
Across all tracked assignees
USPTO PatentsView assignee record - 7 granted patents across 8 technology areas, active 2019–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
The verdict
Baker holds 7 US patents across 8 technology areas, rank #34,395 of 50,000 tracked assignees.
Baker Heart AND Diabetes Institute has been granted 7 US utility patents between 2019 and 2025, placing Baker Heart AND Diabetes Institute at rank #34,395 across all assignees tracked by PlainPatent. This portfolio spans 8 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.6 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Baker Heart AND Diabetes Institute is one of the more focused assignees in the PatentsView dataset. By volume, Baker sits between B&W Tek, Inc. (7 patents, rank #34,391) and BASF Agricultural Solutions US Llc (7 patents, rank #34,399) - the closest US assignees by grant volume. The composite Innovation Score of 47.7/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 6 grants, compared with 1 in the 2015–2019 window, a +500% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Baker Heart AND Diabetes Institute's 17.6 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 8 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Baker Heart AND Diabetes Institute against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
B&W Tek, Inc.
7 patents
BAE Systems Rokar International Ltd.
7 patents
BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD.
7 patents
BAIMMT, LLC
7 patents
BALDWIN JIMEK AB
7 patents
BALSAM INTERNATIONAL UNLIMITED COMPANY
7 patents
BANDALUX INDUSTRIAL, S.A.
7 patents
BASF Agricultural Solutions US LLC
7 patents
BAKER HEART AND DIABETES INSTITUTE
7 patents
What this shows Baker holds 7 patents at rank #34,395, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #34,395 in granted patent volume.
Other assignees with the most granted patents in Baker's primary technology class.
Baker's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
48 Top 18% higher than 82% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2019 | 1 | 14.3% |
| 2022 | 3 | 42.9% |
| 2025 | 3 | 42.9% |
Top 8 of 8 technology areas
Overall rank by patents
#34,395
Across all tracked assignees
47.7 out of 100
How to use this portfolio
Baker's 7 grants land it in the top 18% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.